Literature DB >> 14630506

Levetiracetam treatment of idiopathic generalised epilepsy.

Gregory L Krauss1, Tim Betts, Bassel Abou-Khalil, Gregory Gergey, Helen Yarrow, Akemi Miller.   

Abstract

Levetiracetam (LEV) is effective for treating localisation-related epilepsy, but it is uncertain whether it is effective for treating idiopathic generalised epilepsy. We compared 12-week baseline and LEV treatment periods for patients with generalised seizure types-myoclonic, tonic-clonic and absence seizures--who had failed other anticonvulsants. The majority of 55 patients (76%) had >50% seizure reduction with LEV therapy, 40% became seizure-free; 15% discontinued LEV due to adverse events, mostly sedation. This is preliminary evidence that LEV is effective for treating idiopathic generalised epilepsy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14630506     DOI: 10.1016/s1059-1311(03)00139-0

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  10 in total

1.  Valproate efficacy in absence seizures is hard to beat: lamotrigine comes close.

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2005 Mar-Apr       Impact factor: 7.500

2.  Levetiracetam efficacy in idiopathic generalized epilepsy: long suspected and now confirmed in randomized clinical trials.

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2008 Jan-Feb       Impact factor: 7.500

3.  Juvenile myoclonic epilepsy: more trials are needed to guide therapy.

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2009 Jan-Feb       Impact factor: 7.500

Review 4.  Benefit-risk assessment of levetiracetam in the treatment of partial seizures.

Authors:  Bassel Abou-Khalil
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 5.  Juvenile myoclonic epilepsy: epidemiology, pathophysiology, and management.

Authors:  Timothy E Welty
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

6.  Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus.

Authors:  K-K Tai; D D Truong
Journal:  J Neural Transm (Vienna)       Date:  2007-08-10       Impact factor: 3.575

7.  Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.

Authors:  Maria Stella Vari; Francesca Pinto; Elisabetta Mencaroni; Giovanna Giudizioso; Carlo Minetti; Angela La Neve; Tiziana Francavilla; Marta Piccioli; Salvatore Striano; Luigi del Gaudio; Pierangelo Tovo; Pasquale Striano; Alberto Verrotti
Journal:  Clin Drug Investig       Date:  2016-01       Impact factor: 2.859

8.  Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats.

Authors:  Kenneth V Christensen; Henrik Leffers; William P Watson; Connie Sánchez; Pekka Kallunki; Jan Egebjerg
Journal:  BMC Neurosci       Date:  2010-01-27       Impact factor: 3.288

9.  Levetiracetam in the treatment of childhood epilepsy.

Authors:  James W Wheless
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

10.  Levetiracetam in the treatment of epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.